Search peptides, terms, sources/
Immune and longevity

Thymosin Alpha-1

Also known as: Thymalfasin · Talpha1

Immune-regulating peptide studied in sepsis, pancreatitis and hepatitis B. Not licensed in the UK; meta-analyses show mixed results.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Moderate evidence (level 3 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

3 findings at this grade. 1 further finding at this grade showed no effect and is not counted. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Thymosin Alpha-1 is recorded as not licensed in the UK (checked 14 August 2026).

Best study type
Human trials2 human trials

What is Thymosin Alpha-1?

Thymosin alpha-1 is a naturally occurring 28-amino-acid peptide that regulates immune cells, studied in sepsis, severe acute pancreatitis and chronic hepatitis B. It is not licensed in the UK. The research includes meta-analyses of randomised trials with mixed results, including a large sepsis trial that showed no mortality benefit.

It is the active cleavage product of prothymosin alpha and acts as a Toll-like receptor agonist on dendritic cells. It is authorised as a medicine in some other countries, but not in the UK, EU or US. This page does not assess those products.

Class
Thymic Peptide (Immunomodulator)
Origin
Endogenous
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Thymosin Alpha-1 work?

Thymosin alpha-1 activates Toll-like receptors, mainly TLR9, on dendritic cells, which help start immune responses. This is reported to promote regulatory T cells and signalling molecules such as interferon-gamma. It is described as rebalancing immune activity rather than just boosting it.

The mechanism in more detail

Thymosin Alpha-1 acts primarily as a Toll-like receptor agonist, engaging TLR9 and, in some of the reviewed literature, TLR2, TLR3, TLR4 and TLR7 in specific contexts, on dendritic cells. This activation induces indoleamine 2,3-dioxygenase (IDO) expression via a MyD88-dependent pathway, which promotes regulatory T-cell generation and interleukin-10 production, while also stimulating Th1-associated cytokine production (interferon-gamma, interleukin-2) and dendritic-cell maturation. The peptide is consistently described in the literature reviewed as an immunomodulator that recalibrates T-cell maturation and Th1/Th2 balance, rather than as a general immune stimulant.

Two 2025 systematic reviews and meta-analyses, both PRISMA-based, examined thymosin alpha-1 in acute illness. In sepsis (11 randomised controlled trials, 1,927 patients, all conducted in China), thymosin alpha-1 was associated with reduced 28-day mortality in the pooled analysis, but this benefit was no longer statistically significant when the analysis was restricted to high-quality or multi-centre studies alone, and the review’s own trial sequential analysis indicated the evidence base remains statistically underpowered. In severe acute pancreatitis (5 randomised controlled trials, 706 patients), thymosin alpha-1 was associated with increased CD4+ T-cell counts, a reduced rate of extrapancreatic infection, and improved illness-severity scores, but showed no significant difference in length of hospital stay.

In chronic hepatitis B, a meta-analysis of 4 trials (199 patients) found no significant advantage for thymosin alpha-1 over interferon-alpha at the end of 6 months of treatment, and a significantly lower complete-response rate (odds ratio 0.54, 95% CI 0.30 to 0.97). Six months after treatment ended, thymosin alpha-1 had higher odds of virological, biochemical and complete response. Across these studies, thymosin alpha-1’s evidence base is more recent and methodologically developed than that of many peptides in this catalogue, but the reviewing authors themselves caution that several results depend heavily on a small number of large trials, and that patient-centred outcomes such as mortality and length of stay have not consistently improved even where immune-marker and infection-rate outcomes have.

Mechanisms and targets

Dendritic-Cell MaturationRegulatory T-Cell InductionTh1-Cytokine StimulationTLR9 Agonism (Dendritic Cells)Dendritic CellsT-LymphocytesToll-like Receptor 9 (TLR9)

Classification and structure

Names
Thymosin Alpha-1; Thymalfasin (INN); Talpha1
Class
Thymic Peptide (Immunomodulator)
Origin
Endogenous
Structure
A 28-amino-acid, N-terminally acetylated acidic peptide (molecular weight approximately 3,108 Da), first isolated from calf thymus tissue in 1977. The biologically active cleavage product of the precursor protein prothymosin alpha, generated by cleavage via the lysosomal enzyme legumain (asparaginyl endopeptidase).
Routes used in the research
Subcutaneous injection in the sepsis, severe acute pancreatitis and chronic hepatitis B trial literature reviewed.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Thymosin Alpha-1 has 5 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

5 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
10400

1 of the findings graded Moderate showed no effect, so it is not counted in the evidence grade at the top of the page.

Sepsis 28-day mortality Moderate

A 2025 systematic review and meta-analysis of 11 randomised controlled trials (1,927 adult sepsis, severe sepsis and septic shock patients) found thymosin alpha-1 associated with reduced 28-day mortality overall (odds ratio 0.73, 95% CI 0.59 to 0.90, p=0.003), but this benefit was not statistically significant when restricted to high-quality studies alone (odds ratio 0.82, 95% CI 0.65 to 1.03, p=0.09) or to multi-centre studies alone (odds ratio 0.86, 95% CI 0.68 to 1.08, p=0.20). Trial sequential analysis indicated the current evidence base is statistically underpowered and at risk of false-positive conclusions; publication bias was detected.

Study type
Human trial
Population
Adult sepsis, severe sepsis and septic shock patients, 11 pooled randomised controlled trials, all China-based, 1,927 total patients
Source
1 Gu et al., 2025

Limitation: All 11 trials China-based; small individual trial sizes; combination-therapy trials excluded; sepsis diagnostic criteria inconsistent across the trials' publication years; detected publication bias.

Limitations in full

All 11 trials China-based; small individual trial sizes; combination-therapy trials excluded; sepsis diagnostic criteria inconsistent across the trials' publication years; detected publication bias. This is a genuinely mixed finding, not a clean positive: the headline pooled result and the quality-restricted result disagree, and both are stated here.

The TESTS trial Moderate No effect shown

In the TESTS trial (1,106 adults with sepsis at 22 centres in China, also included in the 2025 sepsis meta-analysis above), 28-day all-cause mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo (hazard ratio 0.99, 95% CI 0.77 to 1.27, p=0.93). Secondary and safety outcomes did not differ. Prespecified subgroup analyses showed differences by age and in people with diabetes.

Study type
Human trial
Population
Adult sepsis patients, 22 centres in China, 1,106 randomised (552 thymosin alpha 1, 554 placebo)
Source
2 Wu et al., 2025

Limitation: A null result on the primary endpoint, which tempers any strong-evidence framing for sepsis.

Limitations in full

A null result on the primary endpoint, which tempers any strong-evidence framing for sepsis. All centres were in China. In the subgroups, the hazard ratio was 1.67 (95% CI 1.04 to 2.67) under age 60 and 0.81 (0.61 to 1.09) at 60 and over, and 0.58 (0.35 to 0.99) in people with diabetes. Subgroup results can arise by chance. The trial report has a published erratum.

Severe acute pancreatitis trials Moderate

A 2025 systematic review and meta-analysis of 5 randomised controlled trials (706 patients with severe acute pancreatitis, 4 rated high-quality by Jadad score) found thymosin alpha-1 associated with increased CD4+ T-cell counts and CD4+/CD8+ ratio, reduced extrapancreatic infection rate (relative risk 0.56, 95% CI 0.40 to 0.78, p=0.0005) and improved APACHE II severity scores (mean difference -1.52, p<0.0001), but no significant difference in length of hospital stay and inconsistent CRP-reduction effects across dose levels.

Study type
Systematic review, Meta-analysis
Population
Adults with severe acute pancreatitis, 5 pooled randomised controlled trials (2 English-language, 3 Chinese-language), 706 patients
Source
3 Tian et al., 2025

Limitation: Small number of pooled trials (5); dosing heterogeneity; the authors themselves state outcome measures for mortality and adverse events were insufficient to draw firm conclusions; mixed-language evidence base.

Chronic hepatitis B comparison Moderate Mixed results

A meta-analysis of 4 randomised controlled trials (199 patients with chronic hepatitis B) compared thymosin alpha-1 with interferon-alpha. At the end of 6 months of treatment, thymosin alpha-1 was not significantly better for virological response (odds ratio 0.62, 95% CI 0.35 to 1.10) or biochemical response (odds ratio 0.60, 95% CI 0.34 to 1.05), and complete response was significantly lower than with interferon-alpha (odds ratio 0.54, 95% CI 0.30 to 0.97). Six months after treatment ended, thymosin alpha-1 had higher odds of virological response (odds ratio 3.71, 95% CI 2.05 to 6.71), biochemical response (odds ratio 3.12, 95% CI 1.74 to 5.62) and complete response (odds ratio 2.69, 95% CI 1.47 to 4.91). The authors say the results mostly apply to HBeAg-negative patients, because three of the four trials were in that group. The abstract does not report side effects.

Study type
Meta-analysis
Population
HBV-DNA-positive chronic hepatitis B patients with elevated liver enzymes, 4 randomised controlled trials, 199 patients, predominantly male, aged 40 to 47
Source
4 Yang et al., 2008

Limitation: Small pooled sample (199 patients).

Limitations in full

Small pooled sample (199 patients). Results differ by time point: no significant advantage over interferon-alpha at the end of treatment, a significantly lower complete-response rate, and higher odds of response 6 months after treatment ended. Mostly HBeAg-negative patients (3 of 4 trials), and mostly male, which limits how far the results apply. The odds ratios are from the published abstract; the full text was not read.

Toll-like receptor mechanism Preliminary

Thymosin alpha-1 exerts its immunomodulatory effects mechanistically via Toll-like receptor 9 agonism, and in some contexts TLR2, TLR3, TLR4 and TLR7 agonism, on dendritic cells. This induces indoleamine 2,3-dioxygenase expression via a MyD88-dependent pathway, and promotes regulatory T-cell generation and Th1-cytokine production, including interferon-gamma and interleukin-2.

Study type
Academic publication, Narrative review
Population
Mechanistic and preclinical narrative-review literature; not a single clinical population
Source
5 Tao et al., 2023

Limitation: Narrative review of mechanistic and preclinical data, not itself a clinical efficacy or safety finding.

What safety findings have been reported?

3 safety findings are recorded for Thymosin Alpha-1. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Hepatitis B meta-analysis, side effects not reported in the abstract

The abstract of the 2008 meta-analysis comparing thymosin alpha-1 with interferon-alpha in chronic hepatitis B (4 trials, 199 patients) does not report side effects. This page therefore makes no safety statement from it.

Source
4 Yang et al., 2008

No sepsis adverse-event synthesis

The 2025 sepsis systematic review and meta-analysis (11 randomised controlled trials, 1,927 patients) does not report a detailed adverse-event profile in the summary reviewed; its focus is mortality and clinical-improvement efficacy outcomes, not a dedicated safety analysis. No dedicated adverse-event synthesis for the sepsis trial population has been identified.

Source
1 Gu et al., 2025

Authors state safety data insufficient

The 2025 severe acute pancreatitis systematic review and meta-analysis (5 randomised controlled trials, 706 patients) states the authors themselves judged outcome measures for mortality, clinical symptoms and adverse events insufficient to draw firm safety conclusions, an explicit source-stated data gap rather than a claim of safety.

Source
3 Tian et al., 2025

What is Thymosin Alpha-1's UK regulatory status?

Marketing authorisation
No UK marketing authorisation identified for thymosin alpha-1, thymalfasin or Zadaxin. A search of EMA centralised authorisations found none. This is a search result, not a confirmed exhaustive absence.
Prescription status
Not applicable in the UK, no licensed UK product exists to classify. Any UK supply would fall under the unlicensed medicine or specials-import framework (Human Medicines Regulations 2012, SI 2012/1916, Regulation 167).
Medicine class
Not a licensed medicine in the UK or centrally in the EU. Licensed as Zadaxin/thymalfasin in a significant number of non-UK, non-EU-centralised jurisdictions; see research-use status.
MHRA position
Unlicensed in the UK. No UK clinical-trial authorisation activity for thymosin alpha-1 has been identified.
Authorised use
None in the UK or centrally in the EU. Outside the UK and EU, thymalfasin/Zadaxin is approved for chronic hepatitis B, and in a subset of approving jurisdictions for chronic hepatitis C and as an immune-response adjunct to vaccination in immunocompromised patients, reported as more than 30 countries by one independent academic source (2010) and more than 35 countries by another (2020). Has never received full US FDA marketing approval for any indication; holds FDA orphan drug designation only, not approval, for malignant melanoma and hepatocellular carcinoma. Designation is a development incentive, not an approval, and this distinction is deliberately not blurred here.
Research use
Actively studied in modern (2024 to 2025) peer-reviewed randomised controlled trials and systematic reviews, predominantly China-based, across sepsis and severe acute pancreatitis. No current UK clinical-trial activity has been identified.
Other restrictions
Not identified as a controlled substance under UK Misuse of Drugs legislation. No MHRA public safety notice naming thymosin alpha-1 has been identified.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Thymosin Alpha-1 is recorded as not licensed in the UK (checked 14 August 2026).

References

6 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Gu et al. (2025). Efficacy of thymosin alpha 1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Cellular and Infection MicrobiologyMeta-analysis, RCT, Systematic review · DOI 10.3389/fcimb.2025.1673959 · PMID 40969554 · Original ↗
  2. Wu J, Pei F, Zhou L, et al.; TESTS study collaborator group (2025). The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ, 388:e082583Human clinical trial, RCT · DOI 10.1136/bmj-2024-082583 · PMID 39814420 · Original ↗
  3. Tian Y, Yao J, Ma Y, et al. (2025). Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis. Frontiers in ImmunologyMeta-analysis, RCT, Systematic review · DOI 10.3389/fimmu.2025.1571456 · PMID 40599771 · Original ↗
  4. Yang YF, Zhao W, Zhong YD, et al. (2008). Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: A meta-analysis. Antiviral ResearchMeta-analysis, RCT · DOI 10.1016/j.antiviral.2007.10.014 · PMID 18078676 · Original ↗
  5. Tao N, Xu X, Ying Y, Hu S, Sun Q, Lv G, Gao J (2023). Thymosin alpha1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application. MoleculesNarrative review · DOI 10.3390/molecules28083539 · PMID 37110771 · Original ↗
  6. MHRA Guidance on unlicensed medicinal products ("specials"), Guidance Note 14. GOV.UK / MHRARegulatory / legislative document · Original ↗

Questions about Thymosin Alpha-1

What is Thymosin Alpha-1?

Thymosin alpha-1 is a naturally occurring 28-amino-acid peptide that regulates immune cells, studied in sepsis, severe acute pancreatitis and chronic hepatitis B. It is not licensed in the UK. The research includes meta-analyses of randomised trials with mixed results, including a large sepsis trial that showed no mortality benefit. Read what it is.

Is Thymosin Alpha-1 licensed in the UK?

PeptGuru records Thymosin Alpha-1's UK status as: Not licensed in the UK. No UK marketing authorisation identified for thymosin alpha-1, thymalfasin or Zadaxin. UK status checked 14 August 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Thymosin Alpha-1 show?

PeptGuru records 5 research findings for Thymosin Alpha-1: 2 from human trials and 3 from regulatory or other records. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Thymosin Alpha-1?

3 safety findings are recorded, including: hepatitis B meta-analysis, side effects not reported in the abstract; no sepsis adverse-event synthesis; authors state safety data insufficient. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Thymosin Alpha-1?

All 6 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Evidence update · The TESTS sepsis trial is now cited to its primary paper (BMJ 2025).

How findings are graded: the grading method. All changes.

  • KPVLys-Pro-Val

    Three-amino-acid fragment of alpha-MSH, studied in cell and mouse models of inflammation. Not licensed in the UK. No human trial of KPV was found.

    Immune and longevityAnimal studiesEvidence reviewed
    PreliminaryNot licensed in the UK
  • Elamipretide

    Synthetic four-amino-acid peptide studied in rare mitochondrial diseases. US accelerated approval for Barth syndrome; not authorised in the UK. A large phase 3 trial failed.

    Immune and longevityHuman trialsEvidence reviewed
    PreliminaryNot licensed in the UK
  • EpithalonEpitalon

    Synthetic four-amino-acid peptide studied in ageing research. Not licensed in the UK; evidence is mostly laboratory and animal work from one group.

    Immune and longevityHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • MOTS-cMitochondrial open reading…

    16-amino-acid peptide encoded in mitochondrial DNA, studied in mice and cells. Not licensed in the UK. No published trial gave MOTS-c to people; human studies measured the body's own levels.

    Immune and longevityHuman trialsEvidence reviewed
    PreliminaryNot licensed in the UK

Compare Thymosin Alpha-1 with KPV

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.